Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Microenvironment | 7 | 2026 | 713 | 1.770 |
Why?
|
| B7-H1 Antigen | 3 | 2023 | 136 | 1.560 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 621 | 1.360 |
Why?
|
| Mice, Inbred BALB C | 17 | 2026 | 978 | 1.270 |
Why?
|
| Cancer Vaccines | 8 | 2020 | 191 | 1.140 |
Why?
|
| Anilides | 1 | 2026 | 52 | 0.940 |
Why?
|
| Immunomodulation | 1 | 2026 | 84 | 0.920 |
Why?
|
| B7 Antigens | 1 | 2024 | 17 | 0.850 |
Why?
|
| Pyridines | 1 | 2026 | 255 | 0.850 |
Why?
|
| Cell Line, Tumor | 15 | 2026 | 3748 | 0.830 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1336 | 0.830 |
Why?
|
| CD47 Antigen | 1 | 2023 | 8 | 0.770 |
Why?
|
| CTLA-4 Antigen | 2 | 2020 | 65 | 0.760 |
Why?
|
| Liposomes | 10 | 2020 | 201 | 0.740 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 155 | 0.710 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 1826 | 0.650 |
Why?
|
| Cytokines | 5 | 2024 | 1339 | 0.650 |
Why?
|
| Radiobiology | 1 | 2020 | 3 | 0.640 |
Why?
|
| Melanoma, Experimental | 1 | 2020 | 39 | 0.640 |
Why?
|
| Infectious hematopoietic necrosis virus | 1 | 2019 | 1 | 0.600 |
Why?
|
| Rhabdoviridae Infections | 1 | 2019 | 4 | 0.600 |
Why?
|
| Fish Diseases | 1 | 2019 | 7 | 0.600 |
Why?
|
| Epitopes | 2 | 2021 | 324 | 0.600 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2019 | 126 | 0.590 |
Why?
|
| Tumor Burden | 6 | 2026 | 240 | 0.590 |
Why?
|
| Epidemics | 1 | 2019 | 58 | 0.570 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1590 | 0.570 |
Why?
|
| Breast Neoplasms | 4 | 2026 | 2602 | 0.560 |
Why?
|
| Selection, Genetic | 1 | 2019 | 150 | 0.560 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2019 | 235 | 0.550 |
Why?
|
| Neoplasms | 4 | 2024 | 3016 | 0.550 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 144 | 0.540 |
Why?
|
| Melanoma | 1 | 2024 | 931 | 0.520 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 909 | 0.500 |
Why?
|
| HLA-DR Antigens | 1 | 2017 | 66 | 0.500 |
Why?
|
| Animals | 24 | 2026 | 33912 | 0.490 |
Why?
|
| Fas Ligand Protein | 1 | 2016 | 32 | 0.480 |
Why?
|
| fas Receptor | 1 | 2016 | 40 | 0.480 |
Why?
|
| Evolution, Molecular | 1 | 2019 | 644 | 0.470 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1722 | 0.460 |
Why?
|
| Mice | 16 | 2026 | 18301 | 0.460 |
Why?
|
| CpG Islands | 1 | 2017 | 337 | 0.460 |
Why?
|
| Vaccines, Subunit | 1 | 2015 | 75 | 0.450 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2020 | 511 | 0.430 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 226 | 0.410 |
Why?
|
| Peptide Fragments | 5 | 2020 | 687 | 0.380 |
Why?
|
| Apoptosis | 3 | 2024 | 1827 | 0.380 |
Why?
|
| Peptides | 4 | 2020 | 708 | 0.370 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 500 | 0.370 |
Why?
|
| Ligands | 2 | 2024 | 481 | 0.360 |
Why?
|
| Gold | 2 | 2023 | 53 | 0.330 |
Why?
|
| Metal Nanoparticles | 2 | 2023 | 53 | 0.330 |
Why?
|
| Bacterial Vaccines | 2 | 2021 | 101 | 0.320 |
Why?
|
| Acinetobacter baumannii | 2 | 2021 | 42 | 0.310 |
Why?
|
| Bacterial Outer Membrane Proteins | 2 | 2021 | 116 | 0.310 |
Why?
|
| Spleen | 3 | 2019 | 258 | 0.270 |
Why?
|
| Female | 20 | 2026 | 70963 | 0.250 |
Why?
|
| Interferon-gamma | 5 | 2020 | 544 | 0.240 |
Why?
|
| Disease Models, Animal | 5 | 2026 | 4697 | 0.230 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2026 | 57 | 0.230 |
Why?
|
| Nanoparticles | 5 | 2020 | 310 | 0.220 |
Why?
|
| Adjuvants, Immunologic | 3 | 2016 | 393 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 981 | 0.210 |
Why?
|
| Acinetobacter Infections | 2 | 2021 | 31 | 0.200 |
Why?
|
| Computer Simulation | 2 | 2024 | 674 | 0.200 |
Why?
|
| Gene Silencing | 1 | 2024 | 229 | 0.200 |
Why?
|
| Immunotherapy | 4 | 2024 | 768 | 0.200 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 262 | 0.200 |
Why?
|
| Catalase | 1 | 2023 | 63 | 0.200 |
Why?
|
| Antibodies, Blocking | 1 | 2023 | 47 | 0.190 |
Why?
|
| Organoplatinum Compounds | 1 | 2023 | 34 | 0.190 |
Why?
|
| Leucovorin | 1 | 2023 | 53 | 0.190 |
Why?
|
| Immunity | 3 | 2020 | 178 | 0.190 |
Why?
|
| Fluorouracil | 1 | 2023 | 130 | 0.190 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2020 | 463 | 0.180 |
Why?
|
| Hypoxia | 1 | 2024 | 247 | 0.180 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 235 | 0.170 |
Why?
|
| Antigens, Bacterial | 2 | 2021 | 319 | 0.170 |
Why?
|
| Drug Delivery Systems | 3 | 2020 | 224 | 0.170 |
Why?
|
| Cell Movement | 1 | 2024 | 876 | 0.160 |
Why?
|
| Pneumonia, Bacterial | 1 | 2021 | 78 | 0.160 |
Why?
|
| Relative Biological Effectiveness | 1 | 2020 | 9 | 0.160 |
Why?
|
| Oncorhynchus mykiss | 1 | 2019 | 2 | 0.150 |
Why?
|
| Aquaculture | 1 | 2019 | 6 | 0.150 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2019 | 32 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 223 | 0.150 |
Why?
|
| Iran | 1 | 2019 | 93 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 373 | 0.150 |
Why?
|
| Doxorubicin | 1 | 2020 | 288 | 0.140 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 139 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 127 | 0.140 |
Why?
|
| Protein Unfolding | 1 | 2018 | 13 | 0.140 |
Why?
|
| Drug Synergism | 1 | 2019 | 237 | 0.140 |
Why?
|
| Lactococcus lactis | 1 | 2018 | 6 | 0.140 |
Why?
|
| Sublingual Immunotherapy | 1 | 2018 | 5 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 236 | 0.140 |
Why?
|
| Antigens, Plant | 1 | 2018 | 35 | 0.140 |
Why?
|
| Nanostructures | 2 | 2016 | 69 | 0.140 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 2016 | 33 | 0.140 |
Why?
|
| Disease Progression | 1 | 2024 | 2200 | 0.140 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2016 | 49 | 0.130 |
Why?
|
| Fibrinogen | 1 | 2018 | 170 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 421 | 0.130 |
Why?
|
| Cell Proliferation | 1 | 2024 | 2465 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 493 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2019 | 357 | 0.130 |
Why?
|
| Immunization | 4 | 2021 | 269 | 0.120 |
Why?
|
| Protein Corona | 1 | 2016 | 2 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1216 | 0.120 |
Why?
|
| Poly I-C | 1 | 2016 | 21 | 0.120 |
Why?
|
| Phospholipids | 1 | 2017 | 100 | 0.120 |
Why?
|
| Leishmania major | 1 | 2016 | 27 | 0.120 |
Why?
|
| Neuraminidase | 1 | 2016 | 40 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 4738 | 0.120 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2016 | 50 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2018 | 227 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2019 | 1483 | 0.110 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 201 | 0.110 |
Why?
|
| Cell Line | 2 | 2017 | 2552 | 0.110 |
Why?
|
| Allergens | 1 | 2018 | 344 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 2065 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 787 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2021 | 889 | 0.110 |
Why?
|
| Interleukin-10 | 1 | 2016 | 192 | 0.110 |
Why?
|
| Lipid A | 1 | 2014 | 23 | 0.110 |
Why?
|
| Dendritic Cells | 1 | 2017 | 439 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2015 | 148 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2014 | 121 | 0.100 |
Why?
|
| Humans | 11 | 2024 | 131163 | 0.090 |
Why?
|
| Genotype | 1 | 2016 | 2595 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2017 | 272 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3436 | 0.050 |
Why?
|
| Pregnancy | 1 | 2016 | 7512 | 0.050 |
Why?
|
| Young Adult | 1 | 2016 | 10103 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2023 | 521 | 0.040 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2020 | 46 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 254 | 0.040 |
Why?
|
| Salsola | 1 | 2018 | 1 | 0.040 |
Why?
|
| Surface Properties | 1 | 2018 | 81 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2017 | 114 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2017 | 46 | 0.030 |
Why?
|
| Adolescent | 1 | 2016 | 20987 | 0.030 |
Why?
|
| Fluorescence | 1 | 2017 | 94 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2018 | 188 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2018 | 134 | 0.030 |
Why?
|
| Protein Transport | 1 | 2018 | 366 | 0.030 |
Why?
|
| Transition Temperature | 1 | 2017 | 3 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2018 | 215 | 0.030 |
Why?
|
| Transgenes | 1 | 2018 | 316 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 2016 | 27 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2018 | 732 | 0.030 |
Why?
|
| Psychodidae | 1 | 2016 | 14 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2016 | 33 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 645 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 358 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2019 | 2395 | 0.030 |
Why?
|
| Drug Stability | 1 | 2015 | 56 | 0.030 |
Why?
|
| Base Sequence | 1 | 2019 | 2730 | 0.030 |
Why?
|
| Drug Liberation | 1 | 2015 | 45 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 410 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 136 | 0.030 |
Why?
|
| Adult | 1 | 2016 | 31282 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 826 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 49 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 136 | 0.030 |
Why?
|
| Immunization Schedule | 1 | 2014 | 111 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2014 | 193 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2885 | 0.020 |
Why?
|
| Prognosis | 1 | 2021 | 4886 | 0.020 |
Why?
|
| Inflammation | 1 | 2018 | 1489 | 0.020 |
Why?
|
| Lipids | 1 | 2014 | 569 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 4497 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 12936 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 6196 | 0.010 |
Why?
|